These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16025769)

  • 1. Measuring treatment response in Alzheimer's disease clinical trials.
    Caban-Holt A; Bottiggi K; Schmitt FA
    Geriatrics; 2005 Jun; Suppl():3-8. PubMed ID: 16025769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild cognitive impairment and preclinical Alzheimer's disease.
    Morris JC
    Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
    Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
    Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
    Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
    Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigating patients and caregivers through the course of Alzheimer's disease.
    Aupperle PM
    J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring therapeutic efficacy in patients with Alzheimer's disease: role of instruments.
    Riepe MW; Janetzky W; Lemming OM
    Dement Geriatr Cogn Disord; 2011; 31(3):233-8. PubMed ID: 21474932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and psychological symptoms assessed with the BEHAVE-AD-FW are differentially associated with cognitive dysfunction in Alzheimer's disease.
    Ito T; Meguro K; Akanuma K; Meguro M; Lee E; Kasuya M; Ishii H; Mori E
    J Clin Neurosci; 2007 Sep; 14(9):850-5. PubMed ID: 17587584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical heterogeneity of Alzheimer's disease. Different clinical profiles can predict the progression rate].
    Mangone CA
    Rev Neurol; 2004 Apr 1-15; 38(7):675-81. PubMed ID: 15098191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil in severe Alzheimer's disease.
    Winblad B
    Am J Alzheimers Dis Other Demen; 2009; 24(3):185-92. PubMed ID: 19246572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scales as outcome measures for Alzheimer's disease.
    Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
    Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.